UNSPSC 51142504: Selegiline

This classification denotes a monoamine oxidase inhibitor with the molecular formula C13H17N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6W731X367Q, chemically known as (-)-(r)-n,alpha-dimethyl-n-2-propynylphenethylamine monohydrochloride but generally known as selegiline hydrochloride, which bears US NIH Compound Identifier 26758. European Medicines Agency schedules Selegiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04347MIG.

Most nations schedule selegiline under HS 29214980 and SITC 51454. As of Q4 2014, SELEGILINE remains the US FDA Preferred Term for this commodity. Selegiline bears US NLM identifiers UMLS ID C0036579 and NCI Concept Code C61938. SMILES: CL.N(C(CC1CCCCC1)C)(CC#C)C.

UNSPSC 51142504 Selegiline (Commodity) shows a mismatch between its nominal scope—a specific pharmaceutical product—and the recent state and local opportunities tagged under it. The three most recent solicitations involve athletic training services, general medical aid supplies, and pharmacy benefit management strategy, none of which directly concern selegiline procurement. State and local governments do purchase pharmaceuticals including controlled substances and specialty drugs through their health departments, corrections systems, fire rescue medical services, and employee health plans, but the available records do not show active selegiline-specific solicitations or a pattern of demand under this code in the current market.

The mismatch suggests either a tagging error in the underlying opportunity records or minimal recent solegiline procurement activity at the state and local level. The City of Tucson's athletic training RFP (due June 9, 2026) and the City of Tampa Fire Rescue's medical aid supplies ITB (originally posted April 24, 2026, with a due date listed as April 9, 2025—likely a date error in the source) both concern operational medical services and consumables rather than pharmaceutical products. The Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026) addresses pharmacy benefit structure and contracting models at the state program level, not individual drug procurement. Without recent opportunities explicitly soliciting selegiline or closely related neurological pharmaceuticals, this code currently shows little actionable activity for business development purposes.